Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Instil Bio Inc (TIL)

Instil Bio Inc (TIL)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
16.00 +0.54 (+3.49%) 04/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 16.00 unch (unch) 16:00 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
15.12
Day High
16.22
Open 15.12
Previous Close 15.46 15.46
Volume 40,100 40,100
Avg Vol 72,795 72,795
Stochastic %K 49.14% 49.14%
Weighted Alpha -74.13 -74.13
5-Day Change +0.97 (+6.45%) +0.97 (+6.45%)
52-Week Range 9.62 - 92.00 9.62 - 92.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,368
  • Shares Outstanding, K 6,559
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,140 K
  • EBIT $ -74 M
  • EBITDA $ -70 M
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -2.02
  • Number of Estimates 2
  • High Estimate -1.81
  • Low Estimate -2.23
  • Prior Year -3.74
  • Growth Rate Est. (year over year) +45.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.47 +28.36%
on 04/09/25
Period Open: 17.89
20.27 -21.07%
on 03/24/25
-1.89 (-10.56%)
since 03/21/25
3-Month
12.47 +28.36%
on 04/09/25
Period Open: 19.61
26.80 -40.30%
on 01/28/25
-3.61 (-18.41%)
since 01/21/25
52-Week
9.62 +66.32%
on 06/20/24
Period Open: 10.64
92.00 -82.61%
on 09/13/24
+5.36 (+50.38%)
since 04/19/24

Most Recent Stories

More News
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

TIL : 16.00 (+3.53%)
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

TIL : 16.00 (+3.53%)
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant

Jefferies highlighted SYN-2510 as an “early mover” in the competitive cancer drug space, with significant upside expected from its planned clinical trials.

TIL : 16.00 (+3.53%)
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TIL : 16.00 (+3.53%)
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?

This drugmaker's lead candidate could become a top-selling cancer therapy.

TIL : 16.00 (+3.53%)
SMMT : 25.22 (+2.48%)
BNTX : 101.81 (+3.09%)
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Although death rates for some cancers are declining, the world is facing a sharp increase in cancer...

ONCY : 0.5750 (+2.50%)
ZNTL : 1.3600 (+5.43%)
TIL : 16.00 (+3.53%)
IMRX : 1.3800 (+8.66%)
ZLAB : 29.71 (+3.02%)
ONC.TO : 0.79 (+2.60%)
2 Stocks Up Over 700% in 2024 That Could Soar Even Further

These relatively small companies are developing new cancer therapies that could generate billions in annual sales.

TIL : 16.00 (+3.53%)
SMMT : 25.22 (+2.48%)
Here's Why Everyone's Talking About Summit Therapeutics

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

TIL : 16.00 (+3.53%)
SMMT : 25.22 (+2.48%)
BNTX : 101.81 (+3.09%)
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.

TIL : 16.00 (+3.53%)
SMMT : 25.22 (+2.48%)
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The investigations concern...

TIL : 16.00 (+3.53%)

Business Summary

Instil Bio Inc. is a clinical-stage biopharmaceutical company. It is focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer. Instil Bio Inc. is based in DALLAS.

See More

Key Turning Points

3rd Resistance Point 17.53
2nd Resistance Point 16.87
1st Resistance Point 16.44
Last Price 16.00
1st Support Level 15.34
2nd Support Level 14.68
3rd Support Level 14.25

See More

52-Week High 92.00
Fibonacci 61.8% 60.53
Fibonacci 50% 50.81
Fibonacci 38.2% 41.09
Last Price 16.00
52-Week Low 9.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro